BioMarin Pharmaceutical

Update in progress

BMRN (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

BioMarin Pharmaceutical is a biotechnology company focused on developing and commercializing therapies for rare, life-threatening diseases worldwide. Its approved products include VIMIZIM for MPS IV type A, VOXZOGO for achondroplasia, NAGLAZYME for MPS VI, PALYNZIQ to reduce blood phenylalanine, BRINEURA for Batten disease, ALDURAZYME for alpha-L-iduronidase deficiency, and KUVAN for phenylketonuria. It develops BMN 333 and BMN 351 and is headquartered in San Rafael, California.

Company score

Sentiment: 1.08; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: -0.24; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.78; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.34; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.22; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.65; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive